➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 8,178,083

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,178,083
Title:Treatment of optic neuritis
Abstract: The present invention provides a method for treating a patient having demyelinating optic neuritis (DON) comprising the sequential or simultaneous administration of a steroid compound and an interferon-beta protein. It is found that early, aggressive treatment of IFN-b is beneficial in such a treatment regimen, for example where the interferon-beta protein is administered at a cumulative weekly dose of more than 12 MIL). The method according to the invention is particularly suitable and beneficial for treatment of patients having early stage DON. In particular, the DON that will benefit from being treated according to the present invention may be in subclinical stage.
Inventor(s): Sergott; Robert (Haverford, PA)
Assignee: Ares Trading, S.A. (Aubonne, CH)
Application Number:11/991,026
Patent Claims:see list of patent claims

Details for Patent 8,178,083

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Octapharma Usa Inc CUTAQUIG immunoglobulin g SOLUTION 125668 1 2019-05-03   Start Trial Ares Trading, S.A. (Aubonne, CH) 2025-09-01 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.